University of California

Brett Eugene Lomenick

Jing Huang

Xudong Fu

Nao Jonai

Rui Hao

Michael E Jung

Karen Lynn Reue

Laurent Vergnes

Xiang Yin

Yanpeng Xing

Mansoureh Eghbali

Jingyuan Li

Simon Diep

Thomas M Vondriska

Sarah Warburton

Mariam Aghajan

Heejun Hwang

Min Chai

Gregory Joseph Baker

Randall M Chin

Meisheng Jiang

Samuel Wheeler French

Ronik Khachatoorian

The present disclosure provides compounds of Formula (VIA), Formula (IIIA), Formula (IVA), and Formula (VA). The compounds are prodrugs of alpha-ketoglutarate, alpha-ketobutryrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, which are useful in treating or preventing age related diseases, disorders, or conditions. 

Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof

Disclosed herein are methods for (a) treating, inhibiting, or reducing aging of a subject, (b) treating, inhibiting, or reducing an age-related symptom or an age-related disease in a subject, and/or (c) increasing the lifespan of a subject which comprise administering to the subject one or more ketobutyrate compounds and compositions thereof.

Ketobutyrate compounds and compositions for treating age-related symptoms and diseases

In certain embodiments this invention pertains to the discovery that inhibition of the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) inhibits the aging process. Accordingly, in certain embodiments, methods are provided for inhibiting/slowing aging. The methods typically involve administering to a mammal an agent that inhibits the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) in an amount sufficient to inhibit expression or activity of EIF4A, where the agent is not resveratrol.

Use of Pateamine A for the treatment of age-related muscle wasting

Drug affinity responsive target stability (DARTS) is a method of drug target ID with several significant advantages over current techniques. In certain embodiments the method involves contacting a sample comprising one or more protein target(s) with a test agent to form a sample/test agent mixture; contacting the mixture with a protease; and identifying a protein or protein fragment that is protected from proteolysis, wherein the protection from proteolysis is an indicator that the protein or protein fragment binds to or interacts with the test agent.

Ligand binding stabilization method for drug target identification

Growing community of inventors

Los Angeles, CA, United States of America

Brett Eugene Lomenick